Compare PRME & SPIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | SPIR |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 819.1M |
| IPO Year | 2022 | 2020 |
| Metric | PRME | SPIR |
|---|---|---|
| Price | $3.54 | $22.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $7.56 | ★ $16.40 |
| AVG Volume (30 Days) | ★ 2.5M | 1.6M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 134.98 |
| EPS | ★ N/A | N/A |
| Revenue | $4,632,000.00 | ★ $110,451,000.00 |
| Revenue This Year | $7.06 | $12.31 |
| Revenue Next Year | $47.01 | $22.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 55.28 | 13.15 |
| 52 Week Low | $1.18 | $6.60 |
| 52 Week High | $6.94 | $25.93 |
| Indicator | PRME | SPIR |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 60.12 |
| Support Level | $3.15 | $7.88 |
| Resistance Level | $3.60 | $23.59 |
| Average True Range (ATR) | 0.23 | 2.09 |
| MACD | 0.07 | 0.47 |
| Stochastic Oscillator | 93.44 | 64.80 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Spire Global Inc provides space-based data, analytics, and space services, offering datasets and insights about Earth to support decision-making. It builds, owns, and operates a constellation of nanosatellites that observe the Earth in real time using radio frequency (RF) technology. Additionally, it offers Space Services solutions that allow customers to deploy and scale their own satellite constellations using its platform, ground station network, manufacturing facilities, and launch partnerships. The company derives revenue from providing data, insights and access to its cloud-based technology platform sold on a subscription basis.